| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA782: Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) |
|
Medicine details |
|
| Medicine name | tagraxofusp (Elzonris®) |
| Formulation | intravenous infusion |
| Reference number | 4104 |
| Indication | Monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) |
| Company | Stemline Therapeutics, Inc. |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/02/2021 |
| NICE guidance | ID1556: Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm |